| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Collaboration revenue | 0 | 4,015 | 2,926 | 2,910 |
| In-process research and development | 0 | 0 | - | 6,706 |
| Research and development | 49,193 | 40,451 | 36,872 | 37,200 |
| General and administrative | 10,945 | 10,042 | 10,690 | 9,526 |
| Total operating expenses | 60,138 | 50,493 | 47,562 | 53,432 |
| Loss from operations | -60,138 | -46,478 | -44,636 | -50,522 |
| Interest income | 2,681 | 3,081 | 2,996 | 3,422 |
| Net loss | -57,457 | -43,397 | -41,640 | -47,100 |
| Earnings per share, basic | -0.65 | -0.5 | -0.52 | -0.78 |
| Earnings per share, diluted | -0.65 | -0.5 | -0.52 | -0.78 |
| Weighted average number of shares outstanding, basic | 87,957,868 | 87,010,742 | 79,410,354 | 60,205,327 |
| Weighted average number of shares outstanding, diluted | 87,957,868 | 87,010,742 | 79,410,354 | 60,205,327 |
Immunome Inc. (IMNM)
Immunome Inc. (IMNM)